Regeneron Genetics Center has spent 14 years building one of the most formidable genomic research operations in the pharmaceutical industry today.
The center, known as RGC, serves as the genomic research branch of Regeneron Pharmaceuticals, headquartered in Tarrytown, New York.
Having spent well over a decade expanding its capabilities, RGC has become a specialist in target validation work that sits at the heart of modern drug development.
As artificial intelligence reshapes how medicines are discovered and developed, RGC believes its ability to interpret vast genetic datasets could prove to be a significant competitive advantage.
The center is continuing a massive expansion of its genetic database, deepening a resource that few rivals can match in either scale or analytical depth.
Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, recently sat down with Fierce’s Fraiser Kansteiner for the publication’s “The Top Line” podcast to discuss the centre’s strategic direction.
Deubler outlined the role RGC plays within the broader Regeneron model, and where the unit could be headed as drug development pushes into new technological frontiers.
The conversation also touched on how RGC’s ongoing genetic research has helped deliver recent breakthroughs, including the hearing loss gene therapy Otarmeni.
Regeneron (REGN) has positioned the genetics centre not merely as a research unit, but as a core pillar of its long-term drug discovery strategy.
The ability to collect and, critically, to interpret genetic data at scale is increasingly what separates leading pharmaceutical companies from those still catching up to the AI era.
RGC’s 14-year head start in building this infrastructure means it enters the current period of technological change with a library of genetic insights that took years to accumulate.
As AI tools become more sophisticated, the quality and volume of underlying genetic data will increasingly determine which companies can translate computational power into viable drug candidates.
Regeneron’s genetics centre appears to be betting that its combination of deep data assets and interpretive expertise will keep it ahead of rivals in this rapidly evolving landscape.